LINC00511 competitively endogenously inhibits hsa-miR-29b-3p activity to upregulate vascular endothelial growth factor A (VEGFA), promoting pancreatic ductal adenocarcinoma (PDAC) stemness. Here, VEGFA is linked to pancreatic ductal adenocarcinoma.